Get the Brief
All stories
Big Money Moves

A director's funds bought $20.4 million of Rapport Therapeutics at $21

A Form 4 shows 969,480 shares bought through Sofinnova and SummitTX funds on Oct 28, 2026. The same day, the company priced a $21.00 offering.

Finvestex Desk · 3 min read
A director's funds bought $20.4 million of Rapport Therapeutics at $21 — slide 1 of 6A director's funds bought $20.4 million of Rapport Therapeutics at $21 — slide 2 of 6A director's funds bought $20.4 million of Rapport Therapeutics at $21 — slide 3 of 6A director's funds bought $20.4 million of Rapport Therapeutics at $21 — slide 4 of 6A director's funds bought $20.4 million of Rapport Therapeutics at $21 — slide 5 of 6A director's funds bought $20.4 million of Rapport Therapeutics at $21 — slide 6 of 6
Swipe through 6 slides →

A Form 4 filed with the SEC on Oct 30, 2026 shows that Rapport Therapeutics (RAPP) director James Healy reported buying 969,480 shares of the company's common stock at $21.00 each. The trade date was Oct 28, 2026. That works out to about $20.4 million.

It's the kind of line that gets passed around as an insider buying with his own cash…

Free · No card, no paywall

Keep reading for free.

You’ve read about 15% of this story. Join The Finvestex Brief — free — to unlock every story and archive edition in full, and get the next Brief at 8:45 a.m. ET.

Every trading day · Free · Unsubscribe anytime. By subscribing you agree to our Privacy Policy.

Already subscribed? Enter your email above to unlock this browser.

General market information for educational purposes — not investment advice. Figures come from the linked sources.